Navigation Links
Cogdell Spencer Inc. Announces Increased Earnings in 2008, Cautious Outlook for 2009
Date:2/25/2009

- - 7,972 Costs related to design-build revenue and other sales - 67,112 - 67,112 Selling, general, and administrative - 7,593 - 7,593 ---------- ------------- ------------ ------- Total operating expenses 7,972 74,705 - 82,677 ---------- ------------- ------------ ------- 13,140 4,155 - 17,295 Interest and other income, net 142 12 85 239 Corporate general and administrative expenses - - (2,226) (2,226) Interest expense - - (6,463) (6,463) Provision for income taxes applicable to funds from operations modified - - (140) (140) Non-real estate related depreciation and amortization - (359) (57) (416) Earnings from unconsolidated real estate partnerships, before real estate related depreciation and amortization 7 - - 7 Minority interests in real estate partnerships, before real estate related depreciation and amortization (215) - - (215) ---------- ------------- ------------ ------- Funds from operations modified (FFOM) 13,074 3,808 (8,801) 8,081 Amortization of intangibles related to purchase accounting, net of income tax benefit (42) (3,875) 1,527 (2,390)
'/>"/>
SOURCE Cogdell Spencer Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Cogdell Spencer Inc. Acquires Summit Professional Plaza I and II in Brunswick, Georgia
2. Cogdell Spencer Inc. Reports Third Quarter 2007 Financial Results
3. Cogdell Spencer Announces a $100 Million Development at St. Lukes Riverside Outpatient Campus In Bethlehem, Pennsylvania
4. Cogdell Spencer Inc. Announces Merger with Marshall Erdman and Associates
5. Cogdell Spencer Inc. Announces the Closing of the Marshall Erdman and Associates Merger
6. Cogdell Spencer Inc. Announces First Quarter Earnings Release and Conference Call Notice
7. Cogdell Spencer Inc. Reports First Quarter 2008 Financial Results
8. Cogdell Spencer Announces First Synergy Project in Pensacola, Florida
9. Cogdell Spencer Inc. Reports Third Quarter 2008 Financial Results
10. Cogdell Spencer Inc. Declares Quarterly Dividend and Outlines 2009 Business Strategy
11. Cogdell Memorial Hospital Partners with Healthcare Management Systems
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:CAP Deeming Status Renewed 2Health News:Recovered Lyme Disease and US Track and Field Athlete Attends Movie Premiere of LymeLife 2Health News:Recovered Lyme Disease and US Track and Field Athlete Attends Movie Premiere of LymeLife 3Health News:Recovered Lyme Disease and US Track and Field Athlete Attends Movie Premiere of LymeLife 4Health News:Leveraging Cloud Computing is the Latest Offering by ICG Consulting to Streamline Costs While Delivering Robust Business Process Solutions 2Health News:Leveraging Cloud Computing is the Latest Offering by ICG Consulting to Streamline Costs While Delivering Robust Business Process Solutions 3Health News:Mexican health care program successful at reducing crippling health care costs 2Health News:Mexican health care program successful at reducing crippling health care costs 3Health News:Exercise is safe, improves quality of life in patients with chronic heart failure 2Health News:Exercise is safe, improves quality of life in patients with chronic heart failure 3Health News:New Prostate Cancer Drug May Hold Promise 2Health News:New Prostate Cancer Drug May Hold Promise 3
Breaking Medicine Technology:Pharmacy Technician Employment Increasing Up to 32% By 2016 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 1EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 2EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 3Lakewood Amedex Inc to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains 4904 1Lakewood Amedex Inc to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains 4904 2Lakewood Amedex Inc to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains 4904 3New Fastrack Technology Improves Productivity 55477 1New Fastrack Technology Improves Productivity 55477 2New Fastrack Technology Improves Productivity 55477 3
Other Medicine Technology:Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 2Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 3Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 4Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 5Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 6Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 7Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 8Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 9Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 2Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 3Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 4